CHMP udtrykte ligeledes bekymring over graden af brug af topisk pimecrolimus hos børn under 2 år (ikke godkendt), hvor immunsystemet stadig er under udvikling.
The CHMP also expressed concerns about the degree of use of topical pimecrolimus in children under the age of 2 (not approved) when the immune system is still developing.